Starpharma Holdings Limited

ASX:SPL ISIN:AU000000SPL0

May 26, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Starpharma Holdings Limited Company Summary

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

DIRECTORS / OFFICERS

Jackie Fairley BSc, BVSc (Hons), MBA
Chief Executive Officer
Dr Fairley has over 15 years' experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Mayne Pharma). Prior to joining Starpharma as COO in 2005, she was CEO of Cerylid Biosciences Limited. During her time as CEO of Cerylid, the company generated revenues of over $20 million, raised more than $10 million private equity funding and completed the acquisition and integration of a private kinase company. Prior to joining the biotechnology sector, Dr Fairley spent 5 years as a Vice President for Faulding's injectable division where she was responsible for the group's global business development activities and injectable development program supporting product sales of > $200 million into 70 countries. She is a member of the Federal Government's Pharmaceutical Industry Working Group, and the Victorian Innovation Economy Advisory Board.

ANNUAL REPORT

COMPANY DATA

	Headquarters	Baker Building

		75 Commercial Road

		Melbourne VIC 3004

		AUSTRALIA

	Telephone	+61 3 8532 2700

	Fax	+61 3 9510 5955

	Principal Sector	Health & Pharm

	Principal Industry	Biotechnology

	Listed	2000/09/28

	Homepage	www.starpharma.com

Key Developments: Starpharma Holdings Limited

	Asian Activities Report for October 10, 2011: Carabella Resources (ASX:CLR) Appoints New Managing Director to Strengthen Expertise in the Coal Industry OCT 10, 2011 12:00 - Article Views: 1,473 Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment.

	Starpharma Holdings Limited's (ASX:SPL) Deal With Elanco Triggers a Share Purchase Plan Extension MAY 11, 2009 11:44 - Article Views: 2,277 The Board of Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) has decided to further extend the closing date of the share purchase plan (SPP) due to the Elanco Agreement announcement made today.

	Starpharma Holdings Limited (ASX:SPL) and Elanco Sign A Collaborative Research, License And Commercialisation Agreement MAY 11, 2009 10:32 - Article Views: 1,714 Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company (NYSE:LLY).

	Starpharma Holdings Limited (ASX:SPL) Raises Additional Capital Up To A$4.6 Million Via Institutional Placement APR 7, 2009 09:42 - Article Views: 2,505 Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced a successful capital raising of at least A$4.3 million and up to A$4.6 million, through a private placement to existing and new institutional and sophisticated investors.

	Starpharma Holdings Limited (ASX:SPL) Completes Patient Testing In Retention Of VivaGel Antiviral Activity Study MAR 19, 2009 12:51 - Article Views: 2,326 Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the completion of patient testing in a clinical trial of VivaGel(R) that explores the length of time the antiviral activity of VivaGel remains following application.

	Starpharma Holdings Limited (ASX:SPL) Announces Its Financial Results For The 6 Months Ending 31 December 2008 FEB 19, 2009 17:18 - Article Views: 2,049 Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year.

	Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result FEB 10, 2009 13:47 - Article Views: 1,729 Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) welcomes news that PRO2000 gel, a candidate microbicide similar to Starpharma's own VivaGel(R), has demonstrated partial effectiveness in preventing HIV infection in women. The study also found that 99% of women in the trial reported that they would use a topical microbicide gel that was approved for HIV prevention.

	Starpharma Holdings Ltd (ASX:SPL) Quarterly Activities Report to Dec 31, 2008 FEB 3, 2009 13:40 - Article Views: 989 Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) Quarterly Activities Report to Dec 31, 2008

	Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug DEC 17, 2008 13:19 - Article Views: 1,593 Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.

	Starpharma Holdings Ltd (ASX:SPL) Full License Agreement Signed For VivaGel Coated Condoms DEC 8, 2008 10:04 - Article Views: 1,673 Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) recently announced the Company's most important commercial milestone to date with the signing of a full license agreement with SSL International for the development of the VivaGel(R)-coated condom. SSL manufactures and markets Durex(R), the world's number one condom.